3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Melanoma
2
Uterine Cervical Neoplasms
1
Pancreatic Adenocarcinoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Esophageal Neoplasms
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Cisplatin
32
human papillomavirus vaccine, L1 type 16, 18
16
Brachytherapy
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Paclitaxel
11
Bevacizumab
11
pembrolizumab
10
Platinum
9
1,2-diaminocyclohexaneplatinum II citrate
9
Topotecan
8
Radiotherapy, Intensity-Modulated
8
Radiation
8
Papillomavirus Vaccines
8
atezolizumab
6
Gemcitabine
6
Fluorodeoxyglucose F18
6
Cyclophosphamide
6
tisotumab vedotin
5
fludarabine phosphate
5
fludarabine
5
aldesleukin
5
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Vaccines, Synthetic
4
Nivolumab
4
Immunoglobulin G
4
Disulfides
4
Colposcopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Uterine Cervical Neoplasms
×
Tiragolumab
×
Clear all
NCT04300647
2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2
Completed
172 enrolled
27 charts